North Murray AS har solgt ytterligere 22.006 aksjer og har nå kun 195.377 aksjer igjen.
Med gårsdagens høye volum (over 211.000 aksjer) og over 30.000 aksjer på tirsdag er det fullt mulig at vi endelig er kvitt North Murray AS som aksjonær i Lytix!

Når forventes neste rally?? (oppover)

Ja. I nedoverbakken...... 💩💩

Rally?

RT?

Jøss, fikk påfyll 😀

Gå på toget, kan bli en fin opptur

Bare å være inne nå før mandagen er en glede. Må ha litt takknemlighet at vi er inne nå

Lytix Biopharma får godkjent søknad om millionstøtte
Lytix Biopharma opplyser at Forskningsrådet har godkjent selskapets søknad om inntil 14,3 millioner kroner i støtte fra SkatteFUNN-ordningen.
🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀

Se der ja. Handlet 10.000 aksjer i november til 6,6 og endelig smalt det her🤩🚀 så ikke nyheten før nå. Litt leit her skulle jeg hatt mer før mandags morgen

Hva sa somsa igjen? 🤪

Leste melding en gang til, angrer på at eg ikke kjøpte mer i dag ass. Er jo mega bull. Tror kursen kan gå kjapt over 20 kroner

Lytix deltar i Redeye Theme: Fight Cancer
24. januar 2024.
Kampen mot kreft er et av hovedfokusområdene i den globale bioteknologiindustrien.
Vi har invitert noen av de ledende nordiske selskapene på dette feltet til å gi oppdateringer om deres prioriteringer, utfordringer og forventet fremgang i løpet av 2024.
Arrangementet vil inkludere en introduksjon til temaet av Redeye-analytikerne Richard Ramanius og Christian Binder, som gir en oversikt over det onkologiske landskapet, sentrale trender samt kommersiell og regulatorisk aktivitet.
Bortsett fra individuelle bedriftspresentasjoner inkluderer arrangementet Q&A-sesjoner med hvert selskap samt paneldiskusjoner.


Dette kan og gi et løft i kursen. Lykke til

Nice 🥳🚀kjøpte noe mer i dag

På mandag går raketten Lytix. Gratulerer

Gratulerer. På mandag passerer vi lett 10 kr.
🚀😊👍

Noen med RT?

Kom inn på 6.50. Kursmålet på 14 kr er nok historie nå

ser 10 i dag? snart tomt for aksjer..

Rally kommer å gå enormt bra denne, lykke til alle som sitter.

ser 30kr innen kort tid.

Bare inntekter er x5 nå skal denne fly

Rally

Nå bør det være klart for en solid oppgang i Lytix, legg også merke til at her fremgår også beløpet som Lytix vil motta basert på salg. Inntekt bare for LTX-315 er 5 ganger børsverdi for Lytix.

Oslo, 5 January 2024. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical-stage immuno-oncology company, today announces that its licensing partner Verrica Pharmaceuticals Inc (“Verrica”) has reported that the last patient has been dosed in Part 2 of the Company’s Phase 2 trial of LTX-315 (named VP-315 by Verrica), a potential first-in-class oncolytic peptide, for the treatment of basal cell carcinoma. Verrica has an exclusive worldwide license agreement with Lytix to develop and commercialize VP-315 for dermatologic oncology indications.

Øystein Rekdal, CEO of Lytix, commented on the results: “With this final patient dosing, Verrica has successfully completed the enrollment for Part 2 of their Phase 2 clinical trial for VP-315, a groundbreaking treatment for basal cell carcinoma. This is a significant milestone in their commitment to advancing innovative solutions for patients facing this prevalent form of skin cancer in the U.S. We look forward to the publication of the comprehensive data from their Phase 2 clinical trial later this year.”

Basal cell carcinoma is a widespread skin cancer, and patients often seek alternatives to surgery due to its associated pain, infection risks, and scarring. Verrica's VP-315 program is strategically designed to offer a targeted delivery system for the oncolytic peptide VP-315, which is specially engineered to stimulate the patient's immune system and effectively eliminate cancer cells.

About the Phase 2 Trial of VP-315
The Phase 2 trial is a 2-part, open-label, multicenter, dose-escalation, proof-of-concept study with a safety run-in designed to assess the safety, pharmacokinetics, and efficacy of VP-315 when administered intratumorally to adults with biopsy-proven basal cell carcinoma. The study has enrolled 80 adult subjects with a histological diagnosis of basal cell carcinoma in at least one eligible target lesion. For additional information about this clinical trial, please visit clinicaltrials.gov, identifier NCT05188729.

Under the terms of the license agreement, Lytix was entitled to receive an upfront payment, contingent regulatory milestones based on achievement of specified development goals, and sales milestones, with aggregate payments of up to USD 111 million in total. In addition, Lytix is entitled to receive tiered royalties based on worldwide annual sales.

For more information, please contact:
Gjest Breistein, CFO
E-mail: gjest.breistein@lytixbiopharma.com

Optimum Strategic Communications
Nick Bastin, Jonathan Edwards
E-mail: lytix@optimumcomms.com

Lytix in brief:
Based in Oslo, Norway, Lytix Biopharma is a clinical stage immuno-oncology company developing novel cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient’s immune system to fight cancer. The Company’s technology is based on pioneering research in “host defense peptides” – nature’s first line of defense towards foreign pathogens. Lytix Biopharma’s lead product, LTX-315, is a first-in-class molecule representing a new and superior therapeutic principle to kill cancer cells and boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapies. LTX-315 targets cancer cells and disintegrates their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The Company was listed on Euronext Growth in Oslo in June 2021, following a private placement covered by investors such as PBM Capital, a US based, healthcare-focused investment firm.

Blir det en emi fremover så blir det isåfall en rettet emi uten muligheter for oss å være med. Den dagen det evt. blir emi vil kursen gå rett til himmels siden økomomien da er sikret for videre utvikling. Har selv sikret meg billige aksjer på dette nivået og ser frem til neste melding fra selskapet.

Hva skjer med Lytix...
er veien lang til produktet er på markede ?
Fase II/III ??
Mulig emi ?

Sannsynlig behov for cash eller realisering av tap!
Det er desember vettu ;)

Siste oppdaterte aksjeoversikt iflg. hjemmesiden til Lytix viser at NM AS nå har 516.814 aksjer (oppdaterte pr. 15/12 ser det ut som). Dvs. at NM AS solgte 160.000 aksjer av totalt omsatt 192.600 aksjer den 15/12. Det viser hvor salgspresset kommer fra. Nå vil jeg anta Gjert Munthe er under 500.000 aksjer og ute av listen over 20 største aksjonærer ved neste oppdatering.

North Murray AS har i løpet av 14 dager solgt seg ned fra 840.243 aksjer til 676.814, dvs. at de GM har solgt ca.164.000 aksjer.

Har North Murray mye igjen?

Er det behov for en emisjon i Lytix ?

Når vi blir kvitt med North Murray som lemper ut aksjer (eneste selger) og videre finansieringsplan blir klarert, ser vi helt annet kursnivå!

Er jo egentlig ingen ting nytt her....

Vi er vel snart ned igjen på 4-5 tallet, salgspresset er stort.
l

Nok en flott melding fra Lytix, økte på denne. God RR her på veldig lav mcap

Kursen har falt fra 10+ på lav omsetning så tenker det er på tide og få den over 10 igjen 🎅

Pga. Underliggende børsmelding.

Oslo, 11 December 2023. Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, today announces that data from the ATLAS-IT-04 study has been published a paper entitled “LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes generate tumor specific T cells in patients with metastatic soft tissue sarcoma”. The paper is published in OncoImmunology, a high-profile, open access journal covering tumor immunology and immunotherapy.

The ATLAS-IT-04 trial was an open label, Phase II trial assessing the effect of LTX-315 when used in combination with Adoptive Cell Therapy (ACT) in patients with progressive metastatic soft tissue sarcoma that had failed standard of care of treatment.

The ATLAS-IT-04 trial included intra-tumoral injections of LTX-315 ahead of surgical removal of tumors, followed by in vitro expansion of T cells isolated from the resected tumor. In a second step, the expanded T cells were infused back to the patients. Six heavily pretreated patients were included in the trial and treated with LTX-315, of which four patients proceeded to adoptive T-cell therapy. The treatment was safe, and the best overall clinical response was stabilization of the disease for 208 days. The immune response data from the trial demonstrated that the treatment induces tumor specific T cells in blood, providing proof of concept that LTX-315 generates an immune response that targets the tumor.

Dr. Øystein Rekdal, CEO of Lytix commented: “This Phase II study proofs that it is feasible to combine LTX-315 and adoptive T-cell therapy and confirms that LTX-315 can induce tumor specific immune responses resulting in stabilization of the disease in sarcoma patients with otherwise progressive disease. This proof-of-concept study in patients with an unmet medical need has given us valuable information for further optimization and commercialization of our technology platform.”

The article can be found here: https://www.tandfonline.com/doi/full/10.1080/2162402X.2023.2290900

For more information, please contact:
Gjest Breistein, CFO
E-Mail:gjest.breistein@lytixbiopharma.com

Optimum Strategic Communications
Nick Bastin, Jonathan Edwards
E-mail: lytix@optimumcomms.com

Lytix in brief:
Based in Oslo, Norway, Lytix Biopharma is a clinical stage immuno-oncology company developing novel cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient’s immune system to fight cancer. The Company’s technology is based on pioneering research in “host defense peptides” – nature’s first line of defense towards foreign pathogens. Lytix Biopharma’s lead product, LTX-315, is a first-in-class molecule representing a new and superior therapeutic principle to kill cancer cells and boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapies. LTX-315 targets cancer cells and disintegrates their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The Company was listed on Euronext Growth in Oslo in June 2021, following a private placement covered by investors such as PBM Capital, a US based, healthcare-focused investment firm.

For å se meldingen følg denne linken: https://newsweb.oslobors.no/message/606165

Dette er en automatisk varsel om utsendelse av melding fra Lytix Biopharma AS.

Dersom du ikke ønsker slike varsler i fremtiden kan du følge denne linken: https://newspoint.oslobors.no/unsubscribe/AAAAAGWeiiU.U3QtZ3Jld0BvbmxpbmUubm8/no
For informasjon om hvordan Oslo Børs håndterer personinformasjon: https://www.oslobors.no/Oslo-Boers/Om-Oslo-Boers/Personvernerklaering

________________________________

This message may contain confidential information and is intended for specific recipients unless explicitly noted otherwise. If you have reason to believe you are not an intended recipient of this message, please delete it and notify the sender. This message may not represent the opinion of Euronext N.V. or any of its subsidiaries or affiliates, and does not constitute a contract or guarantee. Unencrypted electronic mail is not secure and the recipient of this message is expected to provide safeguards from viruses and pursue alternate means of communication where privacy or a binding message is desired.
For more information on the processing of your Personal Data by the Euronext Group, please refer to our privacy statement available at: https://www.euronext.com/en/privacy-policy.

Tilbake til 10 kroner pluss nu?🥳

😂😂😂

Sjekk dagens presentation

Skal opp mange kr nå.

Rally kommer

https://www.redeye.se/video/event-presentation/963528/lytix-biopharma-ceo-oystein-rekdal-presents-at-redeye-life-science-day-2023-23-november?utm_source=video&utm_medium=email